Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
7
×
indiana blog main
7
×
indiana top stories
life sciences
national blog main
boston top stories
national top stories
raleigh-durham blog main
raleigh-durham top stories
san francisco blog main
san francisco top stories
boulder/denver blog main
boulder/denver top stories
clinical trials
detroit blog main
detroit top stories
eli lilly
new york blog main
new york top stories
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
fda
national
teva pharmaceutical
amgen
fremanezumab
migraine research foundation
novartis
bristol-myers squibb
calcitonin gene-related peptide
cancer
chronic migraine
drug prices
What
approval
7
×
drug
fda
new
won
migraine
therapy
bio
class
companies
decades
developed
friday
medicines
oral
roundup
treat
acute
address
addresses
advanced
agency
aimmune
allergy
alnylam’s
amgen
approved
approves
arguments
awarded
bff
big
biogen’s
biopharmaceutical
blueprint
cancer
candidates
carries
causes
certain
Language
unset
Current search:
approval
×
" boston blog main "
×
" indiana blog main "
×
@xconomy.com
3 years ago
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
@xconomy.com
4 years ago
Aimmune Awarded First FDA Approval for a Peanut Allergy Therapy
@xconomy.com
4 years ago
FDA OKs Lilly’s Lasmiditan, First New Acute Migraine Drug in Decades
@xconomy.com
5 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: EASL Does It, Alnylam’s BFF, Gene Therapy Deals & More
@xconomy.com
5 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines